0 Cookie Img

Lidocaine Base

Lidocaine Base
Lidocaine Base
Product Code : 17
Product Description

Our organization is ranked amongst the most prominent suppliers and exporters of Lidocaine Base at the best economic prices. The offered medication is a powdered product that is used to prepare a clear, colorless to pale yellow sterile aqueous solution indicated for injection purposes. It is indicated for local or field block anaesthesia and regional anaesthesia that includes paravertebral nerve blocks in horses. This medication is administered intramuscularly and gets easily absorbed by the body. Lidocaine Base is a combination anaesthetic that contains lignocaine hydrochloride and adrenaline as the active ingredient.


Key Points:


  • Sterile packaging

  • No side effects

  •  Longer shelf life





Lidocaine (137-58-6)



AHFS Codes:

24:04.04 52:16.00 24:04.04.08 72:00.00 84:08.00


Dilocaine, L-Caine

ATC code:


Molecular Weight:

234.3373 g/mol

Pub Chem:


Chemical Formula:


Drug Bank:



Typically NLT 98%








For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.


Lidocaine is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidocaine appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidocaine in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.

Mode of Action:

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anaesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their birth in the first place.


Metabolized mainly by O-demethylation, hydroxylation and conjugation, and excretion is primarily by the biliary route.


The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.

General Reference:

1.Khaliq W, Alam S, Puri N: Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004846. Pubmed 2. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499-508. Pubmed

Contact Us

207, Shivalik Plaza, Kapodara, Surat, Gujarat, 394105, India